ESPE2018 Poster Presentations Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P1 (35 abstracts)
Evaluation of Genetic Etiology in Patients with 46,XY Disorders of Sex Development: One Center Experience
Agharza Aghayev a , Guven Toksoy a , Sukran Poyrazoglu b , Birsen Karaman a , Sahin Avci a , Melek Yildiz b , Zehra Yavas Abali b , Umut Altunoglu a , Firdevs Bas b , Feyza Darendeliler b , Seher Basaran a & Oya Uyguner a
aIstanbul Faculty of Medicine, Department of Medical Genetics, Istanbul, Turkey; bIstanbul Faculty of Medicine, Pediatric Endocrinology Unit, Istanbul, Turkey
Background: Disorders of sex development (DSD) are a heterogeneous group of disorders related to sex determination and differentiation. Although several genetic abnormalities have been discovered through genetic analyses, the underlying genetic causes of 30–40% of the 46,XY DSD cases are not yet known.
Aim: To identify genetic defects in patients with 46,XY DSD.
Material and methods: Seventy-six patients with 46,XY DSD were studied. As a first step 56 patients suspected to have androgen insensitivity syndrome and 5alfa reductase deficiency according to their hormonal results are screened for SRD5A2 and AR gene mutations via Sanger sequencing. Twenty two patients who do not carry mutations in these genes and 20 patients suspected to have gonadal dysgenesis or androgen synthesis defects are enrolled into the next step and 31 DSD associated genes are sequenced using in-house-designed next generation sequencing (NGS) targeted gene panel and analyzed for gross deletion/duplication with MLPA.
Results: In the first group, SRD5A2 and AR gene mutations are detected 60.7% of cases. In the second group, seven previously described and 15 suspected rare variants are identified in 10 different genes within a total 19 cases, leading to our diagnostic rate to 45.2% for the second group. Highest rate of mutation is identified in HSD17B3 gene (16.7%) which is followed by mutations in DHH, NR5A1, LHCGR, POR, HOXA4, WT1, AR, ZFMP2 and MAP3K1 genes.
Conclusion: Genetic analyses following clinical and hormonal evaluation is essential for the management of patients with 46,XY DSD with a great phenotypic and genetic heterogeneity. NGS targeted gene panel seems powerful tool to detection mutations in DSD.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more